Biswal, Sasmita2013-03-112013-03-112010-06Biswal Sasmita. Novel cardiovascular drugs in clinical trials. Indian Journal of Medical Sciences. 2010 June; 64(6) 285-291.http://imsear.searo.who.int/handle/123456789/145542Cardiovascular diseases remain a major cause of morbidity and mortality worldwide, regardless of the recent advances in medical and surgical treatment, for as life expectancy in the developed countries increases, cardiovascular conditions affecting the elderly also rises. Atherosclerosis and cardiovascular diseases take a huge toll on the society, making them the leading cause of death in developed countries. Phenomenal advances in the pathophysiology of cardiovascular disease and the molecular signaling pathways has revealed the role of endothelial dysfunction involved therein and thus has raised the possibility of novel therapeutic targets. Such potential cellular targets include the vascular smooth muscle cells, monocyte/macrophage cell lines, platelets, and endothelial cells. Certain studies affirm that antiplatelet agents, antioxidant therapies, amino acid supplementation, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers may prevent or slow the progression of the disease process. The race is on for new medicines that can treat and prevent heart attacks and strokes, arising out of atherosclerosis, which kills nearly 1 million people a year in the U.S.A alone.enAtherosclerosiscardiovascular drugsclinical trialsnovel agentsAtherosclerosis --drug therapyAtherosclerosis --mortalityCardiovascular Agents --therapeutic useCardiovascular Diseases --drug therapyCardiovascular Diseases --mortalityClinical Trials as Topic --trendsDeveloping CountriesHumansArticle